Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Cheson Bruce D.; Trneny Marek; Bouabdallah Kamal; Dueck Gregory; Gribben John; Lugtenburg Pieternella J.; Press Oliver; Salles Gilles A.; Fingerle-Rowson Gunter; Mattiello Federico; Wassner-Fritsch Elisabeth; Sehn Laurie H.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

【24h】

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

机译：Obinutuzumab Plus Bendamustine，然后是obinutuzumab维持延长总存活的与单独的人类难以单独的肺蛋白蛋白质患者进行整体存活术中，令人难以抑制惰性非霍格金淋巴瘤的患者：Gadolin研究的更新结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Cheson Bruce D.; Trneny Marek; Bouabdallah Kamal; Dueck Gregory; Gribben John; Lugtenburg Pieternella J.; Press Oliver; Salles Gilles A.; Fingerle-Rowson Gunter; Mattiello Federico; Wassner-Fritsch Elisabeth; Sehn Laurie H.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
专利

1. Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study [J] . Cheson Bruce D., Trneny Marek, Bouabdallah Kamal, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Obinutuzumab Plus Bendamustine，然后是obinutuzumab维持延长总存活的与单独的人类难以单独的肺蛋白蛋白质患者进行整体存活术中，令人难以抑制惰性非霍格金淋巴瘤的患者：Gadolin研究的更新结果
2. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study [J] . Cheson Bruce D., Chua Neil, Mayer Jiri, Journal of Clinical Oncology . 2018,第22期

机译：Rituximab-难治性惰性非霍奇金淋巴瘤患者的整体存活益处均接受obInutuzumab加弯蛋白诱导和替代杜鹃花维持的加殖林研究
3. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study (vol 36, pg 2259, 2018) [J] . Cheson Journal of Clinical Oncology . 2018,第26期

机译：Rituximab-难治性惰性非霍奇金淋巴瘤患者的整体生存效益均接受obInutuzumab加弯蛋白诱导和obInutuzumab维持在Gadolin研究中（Vol 36，PG 2259,2018）
4. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone [O] . Bruce D. Cheson, Peter C. Trask, John G. Gribben, -1

机译：GADOLIN III期研究使用奥比妥珠单抗联合苯达莫司汀与单独苯达莫司汀治疗的利妥昔单抗难治性惰性非霍奇金淋巴瘤非霍奇金淋巴瘤患者健康相关的生活质量和症状
5. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study [O] . Bruce D. Cheson, Neil Chua, Jiri Mayer, 2018

机译：Rituximab-难治性惰性非霍奇金淋巴瘤患者的整体存活益处均接受obInutuzumab加弯蛋白诱导和替代杜鹃花维持的加殖林研究

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

著录项

相似文献

相关主题

期刊订阅